191 related articles for article (PubMed ID: 24002590)
1. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer.
Barron TI; Cahir C; Sharp L; Bennett K
Br J Cancer; 2013 Sep; 109(6):1513-21. PubMed ID: 24002590
[TBL] [Abstract][Full Text] [Related]
2. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
Cahir C; Barron TI; Sharp L; Bennett K
Cancer Causes Control; 2017 Mar; 28(3):215-225. PubMed ID: 28210883
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
4. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.
Cahir C; Dombrowski SU; Kelly CM; Kennedy MJ; Bennett K; Sharp L
Support Care Cancer; 2015 Nov; 23(11):3115-30. PubMed ID: 25744290
[TBL] [Abstract][Full Text] [Related]
5. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
7. Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
Kim J; Kim MS; Rajan SS; Du XL; Franzini L; Kim TG; Giordano SH; Morgan RO
Curr Oncol; 2023 Mar; 30(4):3800-3816. PubMed ID: 37185401
[TBL] [Abstract][Full Text] [Related]
8. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
[TBL] [Abstract][Full Text] [Related]
10. Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer.
Cahir C; Dombrowski SU; Kennedy MJ; Sharp L; Bennett K
Psychol Health; 2017 Oct; 32(10):1308-1326. PubMed ID: 28276740
[TBL] [Abstract][Full Text] [Related]
11. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
12. Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women.
Collin LJ; Cronin-Fenton DP; Ahern TP; Goodman M; McCullough LE; Waller LA; Kjærsgaard A; Damkier P; Christiansen PM; Ejlertsen B; Jensen MB; Sørensen HT; Lash TL
Clin Cancer Res; 2021 Mar; 27(5):1421-1428. PubMed ID: 33334905
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer.
Jhawar SR; Alpert N; Taioli E; Sayan M; Bazan J; Park KU; Stover D; Cherian M; White J; Haffty B; Ohri N
Cancer Med; 2020 Nov; 9(22):8345-8354. PubMed ID: 32942344
[TBL] [Abstract][Full Text] [Related]
14. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
15. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
16. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
17. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
18. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
Li CI; Daling JR; Porter PL; Tang MT; Malone KE
Cancer Res; 2009 Sep; 69(17):6865-70. PubMed ID: 19706753
[TBL] [Abstract][Full Text] [Related]
20. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]